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Summary. Background: Oral anticoagulant therapy is
associated with an increased risk of hemorrhage, which
can be assessed by bleeding risk scores. We evaluated the
performance of five validated scores for predicting major
and clinically relevant non-major bleeding events in
patients receiving warfarin. Methods and results: We conducted an ambispective, single-center cohort study of 321
consecutive patients enrolled in an academic anticoagulation clinic. The following scores were calculated: modified
Outpatient Bleeding Risk Index, Contemporary Bleeding
Risk Model, HEMORR2HAGES (Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced
Platelet Count or Function, Re-Bleeding, Hypertension,
Anemia, Genetic Factors, Excessive Fall Risk and
Stroke), ATRIA (Anticoagulation and Risk Factors in
Atrial Fibrillation), and HAS-BLED (Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized
Ratio, Elderly, Drugs/Alcohol). Main outcomes were
major bleeding and a composite of major plus clinically
relevant non-major bleeding. Incidence rates for all group
were 3.8 (95% confidence interval [CI] 2.0–6.4) and 11.9
(95% CI 8.6–16.4) events per 100 patient-years for major
bleeding and major plus clinically relevant non-major
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bleeding, respectively. Agreement among the five scores
was low to moderate (Kendall’s tau-b coefficients 0.22–
0.54). For major bleeding, the c-statistics ranged from
0.606 to 0.735, whereas for major plus clinically relevant
non-major bleeding, they ranged from 0.549 to 0.613. For
all scores, the 95% CI for the c-statistics crossed 0.5 or
was very close. Among high-risk patients, the hazard
ratios for major bleeding ranged from 0.90 to 39.01,
whereas for major plus clinically relevant non-major
bleeding, they ranged from 1.52 to 8.71. For intermediate-risk patients, no score, except the Contemporary Bleeding Risk Model, produced statistically significant hazard
ratios. Conclusion: The scores demonstrated poor agreement and low to moderate discriminatory ability. General
clinical implementation of these scores cannot be recommended yet.
Keywords: bleeding; prognosis; risk; risk assessment; warfarin.

Introduction
Oral anticoagulants have been in use for longer than
60 years for the primary and secondary prevention of
thromboembolic complications, resulting in substantial
reductions in the risk of venous thromboembolism (VTE)
occurrence or recurrence [1,2]. In the case of patients with
atrial fibrillation (AF), adjusted-dose warfarin has been
shown to reduce the relative risk of ischemic stroke and
all-cause mortality in high-risk patients, and current
guidelines suggest a rather liberal use of anticoagulant
prophylaxis [3–7].
However, despite their proven benefit, the use of oral
anticoagulants is associated with an increased risk of
major bleeding (MB) averaging 1% per year in VTE
patients [8] or as high as 4.2–7% in data derived from
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randomized trials or observational studies in AF [9–13].
Furthermore, the incidence of intracranial hemorrhage is
estimated at 0.2% per year [9]. Therefore, a number of
consensus statements have postulated the need for assessing the patient’s bleeding risk prior to initiating oral anticoagulants [6,9]. In practice, this assessment has been
based on the perceived risks and benefits for each patient,
and therefore it might be highly variable and difficult to
standardize. For these reasons, several attempts have been
made to develop tools that allow for a more systematic
bleeding risk assessment. Several scores for predicting
bleeding risk have been published for patients with AF or
VTE [14–21]. All of these scores have categorized patients
into low, intermediate, or high bleeding risk groups but
with significant differences across studies. Furthermore,
few studies validating these bleeding risk scores (BRSs)
and their performance in clinical practice have been conducted some of them suggesting inadequate predictive
ability [19,22]. Additionally, these scores have all focused
on MB events, but none has evaluated the occurrence of
other bleeding events that may not be defined as major
but are still clinically relevant, either because they result
in an increased use of medical resources or because they
cause inconvenience, discomfort, or temporary disability.
We aimed to evaluate the clinical performance, risk
stratification agreement, and ability to predict MB and
clinically relevant non-major bleeding (CRNMB) events
of five validated BRSs in a group of patients on warfarin
therapy for different indications.

Outcome events that occurred during the follow-up period were identified from clinic charts, hospital charts,
clinic database, and emergency department encounters.
When appropriate, hospital charts were reviewed to
obtain pertinent clinical information. Adjudication of
bleeding events was done by one author using the criteria
described hereafter and independently corroborated by a
second author. Both authors were blinded to the patients’
BRSs.
Information at the first clinic visit was used to calculate
patients’ MB risk using the following BRSs: modified Outpatient Bleeding Risk Index (mOBRI) [14], Contemporary
Bleeding Risk Model (CBRM) [21], HEMORR2HAGES
(Hepatic or Renal Disease, Ethanol Abuse, Malignancy,
Older Age, Reduced Platelet Count or Function,
Re-Bleeding, Hypertension, Anemia, Genetic Factors,
Excessive Fall Risk and Stroke) [19], HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol) [23] and ATRIA
(Anticoagulation and Risk Factors in Atrial Fibrillation)
[18]. For each BRS, patients were categorized as being at
low, moderate, or high risk for MB. The mOBRI has been
tested and validated in populations with mixed indications
[14,23], the CBRM was developed in elderly patients, and
HAS-BLED and ATRIA were developed specifically in an
AF populations. The HEMORR2HAGES score was developed for elderly patients with AF. A description of the
bleeding risk tools and the variables included to predict
MB is found in Supporting Information Table S1.

Methods
Study objectives and clinical outcomes
Study design and patient population

The study was conducted at the Anticoagulation Clinic
of the London Health Sciences Centre, University Hospital in London, Ontario, Canada, which primarily monitors
patients
with
cardiac
indications
for
anticoagulation. All patients referred to the clinic have
clinical information routinely and prospectively collected
at the first clinic visit—including thromboembolic and
bleeding risk factors—using standardized forms. We conducted an ambispective cohort study of all consecutive
new patients referred to the clinic for warfarin anticoagulation management between September 2008 and February 2011. Patients were included if they had been
initiated and/or maintained on warfarin therapy and
monitored through the clinic. The study was approved
by the Office of Research Ethics at the University of
Western Ontario.
Patient demographics, indications for anticoagulation,
alcohol and smoking history, laboratory measurements,
comorbidities, concomitant medications, potential bleeding risk factors, and BRSs were collected at the first clinic
visit using a standardized form. Renal impairment was
defined as an estimated creatinine clearance < 30 mL min 1.

The objectives of this study were (i) to determine the agreement between the BRS in their stratification of patients
into low, moderate, and high bleeding risk categories and
(ii) to evaluate the ability of each tool to predict bleeding
events. The main clinical outcomes of the study were (i)
the occurrence of an MB event defined according to the
International Society on Thrombosis and Haemostasis [24]
(including fatal bleeding and/or symptomatic bleeding in a
critical area or organ and/or bleeding causing a fall in
hemoglobin level ≥ 20 g L 1 or leading to transfusion of
≥ 2 units of whole blood or red blood cells) and (ii) the
occurrence of either an MB or a CRNMB event, the latter
defined as those bleeding events not meeting the criteria
for MB but associated with medical intervention, unscheduled contact with a physician, temporary cessation of drug
therapy, or any other discomfort such as pain or impairment of activities of daily life.
Statistical analysis

Due to the ambispective nature of the study, we conducted a post-hoc power analysis to determine the appropriateness of our sample size to independently evaluate
© 2013 International Society on Thrombosis and Haemostasis
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each BRS as a single covariate using Cox regression. We
estimated that a sample size of 321 patients achieved at
least 83% power to detect a hazard ratio of 3 at the 0.05
level of significance level adjusted for an anticipated event
rate of 3%. The sample is not powered to detect superiority of any model over the others.
Categorical data were compared between groups using
v2 or Fisher’s exact tests as appropriate. Continuous data
were compared using Student’s t-tests or Mann-Whitney
U tests as appropriate. The incidence of MB and
CRNMB was calculated as the number of events per 100
patient-years of follow-up, and 95% confidence intervals
(CIs) were calculated using a mid-P exact test. Agreement
between the bleeding risk tools in stratifying patients into
low, moderate, and high bleeding risk categories was
quantified using Kendall’s tau-b coefficient. The discriminatory ability for both MB and MB plus CRNMB events
was calculated for each tool using c-statistics [25]. Survival analysis was done according to the method of Kaplan and Meier [26]. Hazard ratios (HRs) and 95% CIs for
bleeding risk categories for each tool were estimated with
Cox regression analysis using block entry with each score
entered as an independent covariate. Exploratory analyses
to evaluate adjusted HRs were conducted through stepwise Cox regression. The observation period for each
patient started at the first clinic appointment or on the
day of warfarin initiation if warfarin was started after the
first clinic appointment. Patients were followed until the
occurrence of the first MB or CRNMB event and censored at the time of warfarin discontinuation, last clinic
contact, death, or end of the study period. For all analyses, P values < 0.05 were considered as statistically significant. Analyses were done using Excel 2007 (Microsoft
Corporation, Redmond, WA), OpenEpi version 3.01
(www.openepi.com), and SPSS 20.0 (IBM Corporation,
Armonk, NY).
Results

Table 1 Baseline patient characteristics
Characteristic
Demographics
Mean age (yrs) (SD)
Male gender (%)
Mean body mass index (kg per m2) (SD)
Previously on warfarin (%)
Indication for anticoagulation (%)
Atrial fibrillation/flutter
Cardioembolic stroke
Venous thromboembolism
Prosthetic valve replacement
LV thrombus
Heart failure/cardiomyopathy
Medical conditions (%)
Atrial fibrillation
History of myocardial Infarction
Coronary artery disease
Previous percutaneous intervention
Uncontrolled hypertension (SBP > 160 mm Hg)
Heart failure/cardiomyopathy
Stroke/transient ischemic attack
History of gastrointestinal bleed
History of major bleed
Hepatic dysfunction
Renal dysfunction
Diabetes mellitus
Active malignancy
Current smoker
Concomitant medications
Antiplatelets (%)
Triple therapy (%)
NSAIDs (%)
Cyclooxygenase inhibitors (%)
Selective serotonin reuptake inhibitors (%)
Statin (%)
Amiodarone (%)
Corticosteroids (%)
Proton pump inhibitors (%)
Number of medications per day, mean (SD)
Number of doses per day, mean (SD)

(n = 321)
69.2 (13.4)
57.0
28.8 (5.97)
44.0
74.0
10.5
2.5
10.8
3.2
1.3
78.4
21.0
33.0
17.1
3.8
31.4
39.7
11.2
2.9
0.3
11.8
27.1
5.4
10.2
47.7
3.1
5.3
0.9
8.1
56.1
3.4
1.9
28.7
8 (3.5)
10 (4.9)

SD, standard deviation; LV, left ventricular; NSAIDs, nonsteroidal
anti-inflammatory drugs.

Patient characteristics

Between September 2008 and February 2011, 321 patients
started warfarin therapy management at the clinic and
were included in the analysis. Baseline characteristics are
summarized in Table 1. The cohort was constituted primarily by elderly patients (mean age 69 years), and 57%
were males. The most common indication for anticoagulation was AF (74%), and for these patients, the average
CHADS2 (Congestive heart failure, Hypertension, Age 75
years, Diabetes mellitus, Stroke) score was 2.6 (SD 1.3).
Of the 321 patients, 180 (56%) were warfarin na€ıve at the
time of their first clinic visit. The median length of observation was 319 days (range 20–904). In total, there were
319.3 and 307.3 patient-years of observation when censored at MB event or the composite of MB and CRNMB
event, respectively.
© 2013 International Society on Thrombosis and Haemostasis

Major and clinically relevant non-MB events

During the observation period, 12 MB events occurred,
corresponding to an incidence of 3.8 major bleeds per 100
patient-years (95% CI 2.0–6.4) (Table 2). The description
of the patients experiencing an MB is shown in Supporting Information Table S2. The average  SD age was
71.5  14, and five (41.7%) were male. In eight patients
(58.3%), the indication for anticoagulation was AF, and
the other five patients had prosthetic mechanical heart
valves. The average  SD CHADS2 score in patients with
AF was 3.2  1.3. The mean  SD INR at the time of
event was 5.4  4.3. Warfarin therapy was continued in 6
(50%) of the patients experiencing an MB event.
There were 26 CRNMB events during follow-up, corresponding to an incidence of 8.1 clinically relevant non-
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Table 2 Incidence rate of major and clinically relevant nonmajor bleeding events according to bleeding risk categories
Risk category
Low
Bleeding risk score

Intermediate

High

Events per 100 patient-years [95% CI]

Modified Outpatient Bleeding Risk Index
MB
6.98
MB + CRNMB
9.34
Contemporary Bleeding Risk Model
MB
1.76
MB + CRNMB
9.62
HEMORR2HAGES
MB
1.32
MB + CRNMB
8.20
HAS-BLED
MB
0.00
MB + CRNMB
9.87
ATRIA
MB
2.36
MB + CRNMB
10.18

[1.78–18.99]
[2.97–22.54]

2.63
11.97

[1.07–5.47]
[7.98–17.28]

6.15
14.68

[1.56–16.73]
[6.42–29.03]

[0.56–4.26]
[6.11–14.45]

6.62
16.12

[2.68–13.77]
[9.18–26.42]

79.00
79.00

[13.41–264.3]
[13.41–264.3]

[0.23–4.37]
[4.44–13.94]

3.71
14.06

[1.36–8.23]
[8.6–21.8]

14.68
20.94

[5.37–32.5]
[9.17–41.46]

NE
[2.51–26.86]

2.60
9.07

[0.95–5.76]
[5.46–14.23]

7.38
18.91

[3.23–14.61]
[11.38–29.66]

NE
NE

21.22
34.62

[7.76–46.96]
[16.08–65.76]

[1.03–4.67]
[6.95–14.44]

NE
NE

NE, not estimable; MB, major bleeding; CRNMB, clinically relevant non-major bleeding; HEMORR2HAGES, Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall
Risk, and Stroke; ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol.

major bleeds per 100 patient-years (95% CI 4.8–10.3).
When MB and CRNMB events were combined, the incidence of any bleeding event was 11.9 per 100 patientyears (95% CI 8.6–16.4). One patient experienced an MB
and a CRNMB and was censored at the time of the first
event.
Clinical performance of BRSs

Comparison of the bleeding risk stratification by each
score revealed variable classification of patients into the
three bleeding risk categories, and it is shown along with
the corresponding number of bleeding events in Table 3.
The proportion of patients classified as low, moderate,
and high risk of MB ranged from 10.3% to 91.9%,
29.0% to 69.8%, and 0.9% to 29.6%, respectively. The
agreement between risk scores for classifying patients into
the same risk categories was low to moderate as assessed
by Kendall’s tau-b coefficients: the coefficients for agreement between mOBRI compared with CBRM, HEMORR2HAGES, HAS-BLED, and ATRIA were 0.30,
0.36, 0.41, and 0.25, respectively; for CBRM vs. HEMORR2HAGES, HAS-BLED, and ATRIA, the coefficients were 0.39, 0.34, and 0.22, respectively; for
HEMORR2HAGES vs. HAS-BLED and ATRIA, the
coefficients were 0.54 and 0.36, respectively, and for
HAS-BLED vs. ATRIA, the coefficient was 0.26.
The cumulative incidence of MB in patients classified
as low, moderate, or high risk ranged from 0 to 9.8%,
2.5% to 6.5%, and 6.7% to 66.7%, respectively. In general, the high bleeding risk category had the highest inci-

dence of MB events. The c-statistics for predicting MB
events ranged from 0.606 to 0.735. The scores had even
less discriminatory ability to predict MB plus CRNMB
events, with c-statistics ranging from 0.549 to 0.613.
Unadjusted HRs for MB and the composite of major
plus CRNMB according to risk category are shown in
Table 4. The analysis showed that the mOBRI was
unable to predict MB or MB plus CRNMB. In the case
of the HAS-BLED score, we were unable to estimate
the HR for MB due to the fact that only about 10% of
all patients were included in the low-risk category in
which there were no MB. For patients classified in the
high-risk group, the HEMORR2HAGES, CBRM, and
ATRIA scores reported high HRs for MB with highly
significant P-values, whereas for patient in the moderaterisk category, only the CBRM resulted in an increased
HR that was statistically significant. We did not have
any patients classified in the moderate-risk category
according to the ATRIA score. The analysis of the combined outcome of major plus CRNMB showed that in
the patients categorized in the high-risk group, only the
CBRM and ATRIA scores reported a statistically significant HR, whereas the HEMORR2HAGES score
achieved marginal significance and the HAS-BLED score
did not. For those patients classified in the moderaterisk category, no score demonstrated a statistically significant increase in the HRs of major plus CRNMB,
although a trend was found for the CBRM. Exploratory
analyses using adjusted HRs for additional potential predictors did not show any change in the results (data not
shown).
© 2013 International Society on Thrombosis and Haemostasis
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Table 3 Risk categorization and predictive ability of bleeding risk scores
Bleeding risk categories (n = 321)
Bleeding risk score

Low

Outpatient Bleeding Risk Index
Individuals in risk category, n (%)
MB, n (%)
MB + CRNMB, n (%)
Contemporary Bleeding Risk Model
Individuals in risk category, n (%)
MB, n (%)
MB + CRNMB, n (%)
HEMORR2HAGES
Individuals in risk category, n (%)
MB, n (%)
MB + CRNMB, n (%)
HAS-BLED
Individuals in risk category, n (%)
MB, n (%)
MB + CRNMB, n (%)
ATRIA
Individuals in risk category, n (%)
MB, n (%)
MB + CRNMB, n (%)

Moderate

High

c-Statistic (95% CI)

52 (16.2)
3 (5.8)
4 (7.7)

224 (69.8)
6 (2.7)
27 (12.1)

45 (14.0)
3 (6.7)
7 (15.6)

–
0.606 (0.435–0.777)
0.549 (0.452–0.645)

225 (70.1)
4 (1.8)
21 (9.3)

93 (29.0)
6 (6.5)
15 (16.1)

3 (0.9)
2 (66.7)
2 (66.7)

–
0.714 (0.548–0.879)
0.591 (0.489–0.692)

157 (48.9)
2 (1.3)
12 (7.6)

132 (41.1)
5 (3.8)
19 (14.4)

32 (10.0)
5 (15.6)
7 (21.9)

–
0.735 (0.583–0.886)
0.613 (0.517–0.709)

33 (10.3)
0 (0.0)
3 (9.1)

193 (60.1)
5 (2.6)
18 (9.3)

95 (29.6)
7 (7.4)
17 (17.9)

–
0.672 (0.523–0.820)
0.587 (0.487–0.686)

295 (91.9)
7 (2.4)
29 (9.8)

0
0
0

26 (8.1)
5 (19.2%)
8 (30.8)

–
0.674 (0.491–0.858)
0.576 (0.470–0.682)

CI, confidence interval; MB, major bleeding; CRNMB, clinically relevant non-major bleeding; HEMORR2HAGES, Hepatic or Renal Disease,
Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive
Fall Risk, and Stroke; ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol.

Table 4 Unadjusted HRs for bleeding events according to bleeding risk scores
Major bleeding plus clinically relevant
non-major bleeding

Major bleeding
Bleeding risk tool

HR (95% CI)

Outpatient Bleeding Risk Index
Low
Reference
Moderate
0.38 (0.09–1.51)
High
0.90 (0.18–4.46)
Contemporary Bleeding Risk Model
Low
Reference
Moderate
3.67 (1.045–13.01)
High
39.01 (6.99–217.70)
HEMORR2HAGES
Low
Reference
Moderate
2.77 (0.54–14.28)
High
10.94 (2.12–56.42)
HAS-BLED*
Low
NE
Moderate
NE
High
NE
ATRIA†
Low
Reference
Moderate
NE
High
9.09 (2.88–28.68)

P value

HR (95% CI)

P value

Reference
1.29 (0.45–3.69)
1.52 (0.44–5.22)

0.636
0.503

Reference
1.79 (0.92–3.48)
8.71 (2.02–37.52)

0.085
0.004

Reference
1.80 (0.88–3.72)
2.54 (1.00–6.46)

0.110
0.050

NE
NE
NE

Reference
0.97 (0.29–3.29)
1.91 (0.56–6.52)

0.959
0.302

NE
< 0.001

Reference
NE
3.52 (1.61–7.69)

NE
0.002

0.169
0.895

0.044
< 0.001

0.224
0.004

NE, not estimable; HR, hazard ratio; CI, confidence interval; HEMORR2HAGES, Hepatic or Renal Disease, Ethanol Abuse, Malignancy,
Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall Risk, and Stroke;
ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol. *There were no major bleeding events in the
low-risk category. †No patients were classified in the moderate-risk category.
© 2013 International Society on Thrombosis and Haemostasis

1652 S. Burgess et al

Discussion
In the present study, we found a moderate correlation
between the tested BRS as the scores often classified the
same patients into different risk categories. A previous
study that assessed the agreement between four scores
including the mOBRI, the schemes published by Kearon
et al. [16] and by Kuijer et al. [15], and HEMORR2
HAGES reported similar results [19]. A more recent comparison of bleeding risk tools (HAS-BLED, mOBRI,
CBRM, Kuijer et al. [15], and HEMORR2HAGES) also
demonstrated variable classification of patients into various bleeding risk categories [20]. The discrepant stratification of bleeding risk could potentially be explained
by methodological or population differences between
studies.
In our study, we also found that the BRSs performed
poorly for predicting MB events and were generally
unable to predict a composite of major plus CRNMB
events. Of the five evaluated scores, we found that the
mOBRI [14] had no predictive ability for MB or the combined outcome, and we believe that this score should not
be used in clinical practice. The HAS-BLED [23] score
was the most conservative, classifying only 10.3% of
patients in the low-risk category, and having the highest
proportion of patients classified as high risk (29.6%).
However, this score failed to achieve an acceptable discriminatory power for MB or major plus CRNMB (c-statistic 0.672 and 0.587, respectively). In general, it is
accepted that a c-statistic > 0.7 has acceptable discrimination and a value > 0.8 has excellent discrimination [27].
In comparison, the CBRM [21] only classified 1%
patients as high bleeding risk, and among those, 66.7%
experienced an MB event. Therefore, this score achieved
a better predictive capacity for MB but not for the combined MB plus CRNMB. The HEMORR2HAGES score
displayed slightly better discriminatory power for both
MB and MB plus CRNMB (c-statistics of 0.735 and
0.613, respectively). The ATRIA score was able to predict
MB and major plus CRNMB for patients classified as
high risk, but this should be interpreted with caution
since no patient was classified in the intermediate-risk
group. Furthermore, when analyzed by c-statistics, it did
not perform appropriately. Three previous studies suggested the HAS-BLED score outperforms other bleeding
risk tools in predicting MB events [20,23,28]. Lip et al.
evaluated the predictive value of several bleeding risk
tools, including HAS-BLED, HEMORR2HAGES, mOBRI, and the CBRM, using data from the SPORTIF
(Stroke Prevention using ORal Thrombin Inhibitor in
atrial Fibrillation) III and IV clinical trials [20]. In their
analysis, the HAS-BLED score exhibited a marginally
better predictive ability compared with the other scores
based on comparative c-statistics. The HAS-BLED
scheme had a c-statistic of 0.66, which is almost identical
to the predictive ability exhibited in our study. In the ini-

tial validation of the HAS-BLED score, it had greater
predictive ability for bleeding events (c-statistic = 0.72)
and outperformed HEMORR2HAGES (c-statistic = 0.66)
[23]. A recent comparison of HAS-BLED and ATRIA
concluded that the former had better performance when
analyzed as a dichotomous score (low-moderate vs. high
risk) but not as a continuous variable. In contrast, in the
present study, the HAS-BLED score did not outperform
other clinical prediction tools. Furthermore, the overlap
of the c-statistic CIs for each score and the lack of
accepted methods to compare multiple c-statistics make it
difficult to evaluate the significance of a slightly greater cstatistic; therefore, we cannot conclude that one score is
superior in predictive ability. Finally, for all five scores,
the 95% CI for the c-statistics either cross 0.5 or are very
close to it, suggesting that the these scores have a discriminatory power similar to or just slightly better than what
would have been expected by chance alone [29].
Our findings are consistent with a recent systematic
review and performance analysis of clinical prediction
rules for MB risk [30]. The authors concluded that none
of the risk scores exhibited sufficient predictive accuracy
or had sufficient validation to be recommended in routine
clinical practice. At least two recently published studies
concluded that the clinical performance of BRS to predict
MB events is limited, and in one of them, the authors
found that the scores performed no better than clinical
gestalt [31,32]. It is possible that a single clinical prediction tool may not be capable of capturing the numerous
variables that are associated with increased bleeding risk.
However, the most recent versions of the Canadian and
European AF guidelines have suggested the use of the
HAS-BLED score for bleeding risk assessment in these
patients [33–36], but based on our results and those of
other authors, we believe that no individual risk scoring
system has sufficient reliability to merit recommendation
for routine clinical use.
Our study has several limitations. First, this was an
ambispective study with all the caveats associated with
the retrospective portion of such design. However, all
patients had clinical information prospectively collected
at the time of their initial assessment using standardized
forms. Also, since the occurrence of bleeding events is
routinely investigated by the pharmacists during routine
monitoring phone calls for warfarin adjustment, we
believe that the chance of missing relevant bleeding events
during the follow-up period was minimal. Second, our
study population is relatively small; however, a power
analysis suggested that the sample size was appropriate to
evaluate the scores using Cox regression, although we
cannot completely rule out the possibility that the relatively low event rate might have influenced some of the
observed variability in the results. Additionally, we had a
relatively short follow-up, and therefore the occurrence of
later events might have been missed. However, our
follow-up is similar to that of other studies. It is always
© 2013 International Society on Thrombosis and Haemostasis
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possible that the bleeding risk varies with time, and it has
been suggested that it might be higher during warfarin
initiation. However, our study included 56% of Warfarinnaive patients, and thus we believe that the bleeding estimates reflect the overall population. Subgroup analyses
did not show any major difference between naive patients
and those who were not, but these are to be taken with
caution given the sample size. Finally, our study reflects
the experience of a single academic center and might differ from other settings. Finally, an important contribution
of our study is that, to the best of our knowledge, it is
the first to evaluate the performance of BRS to predict
CRNMB. Our findings suggest that neither of the tested
scores performs satisfactorily, although it must be considered that these scores were not originally developed to
predict CRNMB. Further studies are needed in this
regard.
In conclusion, in our experience, the BRSs evaluated
herein have at best a moderate agreement in stratification of bleeding risk and a suboptimal ability for predicting MB or a combination of MB and CRNMB.
Therefore, although based on our results we cannot recommend their routine use in clinical practice, they might
be helpful to guide clinical assessments or follow-up
strategies. It should be remembered that all scores provide only a general guidance on how to evaluate a
patient’s bleeding risk but should not be a substitute for
sound clinical judgment and continued clinical surveillance. Additional studies are needed specifically focused
on further refining the previously published BRS, identifying additional clinically relevant variables, evaluating
their clinical impact and developing methods to facilitate
clinical decision making.
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